Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

The UK government is providing £2 million ($2.6 million) in funding to allow digital assessment to be added to a ...